| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2160982 | Radiotherapy and Oncology | 2007 | 5 Pages |
Abstract
We treated 36 cases of stage I/II non-small cell lung cancer in inoperable patients. Treatments were planned to a total isocenter dose of 60Â Gy (8Â ÃÂ 7.5Â Gy) based on a dynamic field shaping arc, employing one arc to span as much area as possible and if needed additional weighted segments. The 2 year infield progression free probability is 65%. Disease-specific survival is 75% at 2 years. No patients experienced grade 3-4 toxicity.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Samuel Bral, Hilde Van Parijs, Guy Soete, Nadine Linthout, Lutgard Van Moorter, Dirk Verellen, Guy Storme,